This post was originally published on this site Campaigns by Movember and the Alberta Cancer Foundation have helped to raise the number of men enrolled to more than 200 in the validation study of ClarityDX Prostate, a new blood screening test developed by Nanostics for the early diagnosis of prostate cancer. Recruitment, which started in June…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Meeting with FDA Supports Tazemetostat for Some Follicular Lymphoma
This post was originally published on this site Epizyme successfully met with the U.S. Food and Drug Administration (FDA) to bolster an upcoming submission of its oral investigational treatment tazemetostat for relapsed or resistant follicular lymphoma, with or without EZH2 activating mutations. The pre-New Drug Application (NDA) meeting is a critical step to ensure a…
Advanced Multiple Myeloma Patients Responding to Janssen’s CAR T-cell Therapy, Trial Data Show
This post was originally published on this site Janssen’s investigational CAR T-cell therapy for multiple myeloma, called JNJ-4528 (JNJ-68284528), safely led to early and deep responses in all patients with relapsed or refractory multiple myeloma treated in the first part of a Phase 1/2 trial. These findings were announced in the oral presentation, “Results from…
Breast Cancer Index Identifies Women Likely to Benefit From Extended Hormone Therapy, Latest Data Show
This post was originally published on this site The Breast Cancer Index, a molecular test developed by Biotheranostics, successfully identified a group of women with hormone receptor (HR)-positive breast cancer who may benefit from long-term hormone therapy with tamoxifen, data from a Phase 3 trial shows. Study findings were presented in a poster, titled “Breast…
Bemcentinib-Keytruda Combo Effective in Some Advanced NSCLC Patients with Poor Prognosis
This post was originally published on this site Combining bemcentinib with Keytruda (pembrolizumab) is effective and delays disease progression in people with previously treated advanced non-small cell lung cancer (NSCLC), particularly in those with AXL-positive tumors. Those updated results from a Phase 2 clinical trial show, to researchers’ surprise, that benefits also were seen in people with low levels of PD-L1…
NICE Recommends Lynparza Tablets for Relapsed, BRCA-mutated Advanced Ovarian Cancers
This post was originally published on this site After an initial rejection due to cost-effectiveness concerns, the U.K.’s National Institute of Health and Care Excellence (NICE) has reversed its decision and is expanding the use of Lynparza (olaparib) tablets to include maintenance therapy for relapsed ovarian cancer patients who responded to platinum-based chemotherapy. The recommendation is…
MGUS Patients Have More Frequent Hospital Visits Prior to Diagnosis than Healthy Controls, Research Shows
This post was originally published on this site People with monoclonal gammopathy of undetermined significance (MGUS), a rarely diagnosed condition that can progress to myeloma, go to the hospital twice as often as people without the condition, new research suggests. This may be helpful in identifying people with MGUS and, by extension, aid in early…
Health Canada Approves Adcetris-Chemo Combo for Initial Peripheral T-cell Lymphoma Treatment
This post was originally published on this site Health Canada has expanded its approval of Adcetris (brentuximab vedotin) in combination with a chemotherapy regimen for the first-line treatment of peripheral T-cell lymphomas expressing the CD30 marker. The approval is for Adcetris in combination with CHP (cyclophosphamide, doxorubicin, prednisone) chemotherapy, and is for people with previously untreated…
Blank Family Foundation Donates $1M to Mount Sinai for Prostate Cancer Research
This post was originally published on this site The Arthur M. Blank Family Foundation has given $1 million to the Icahn School of Medicine at Mount Sinai‘s urology department to support research into prostate cancer. Together with an earlier foundation gift of $500,000, the money will support the New York school’s Prostate Cancer Program, whose mission is to…
Single-Blinded Trial Design Prevents Patients From Withdrawing Prematurely, Analysis Shows
This post was originally published on this site BeyondSpring’s single-blinded trial design, in which patients are unaware of the treatment they receive, effectively prevented participants from prematurely withdrawing from the company’s DUBLIN-3 study due to dissatisfaction with their treatment allocation, an analysis shows. The findings were presented in a poster, titled “Validation of a Single-Blinded…
FDA Approves FoundationOne CDx as Companion Diagnostic Test for Piqray Treatment
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Foundation Medicine’s FoundationOne CDx as a companion diagnostic test for identifying advanced breast cancer patients with a PIK3CA mutation suitable for treatment with Piqray (alpelisib). Piqray was approved in May, in combination with Faslodex (fulvestrant), for postmenopausal women and…
Lower Prostate Cancer Risk in Diabetics Likely Due to Fewer Biopsies, Not Medications, Study Says
This post was originally published on this site Common treatments for diabetes don’t appear to mask or reduce levels of a prostate cancer marker in the blood. Rather, the lower rates of prostate cancer detected in men with diabetes might be because they are less likely to undergo prostate biopsies, a large population-based study from…